1	Toscana Virus Infection Clinical Characterization
2	Nazli Ayhan ^{1,2*} , Carole Eldin ^{1,3} , Remi Charrel ^{1,3,4}
3	
4	
5	¹ Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France.
6	² Centre National de Référence des Arbovirus, Inserm-IRBA, Marseille, France.
7	³ Laboratoire des Infections Virales Aigues et Tropicales, Pole des Maladies Infectieuses, AP-HM Hopitaux
8	Universitaires de Marseille, France
9	⁴ Le Service de Prévention du Risque Infectieux (LESPRI), CLIN AP-HM Hôpitaux Universitaires de Marseille,
10	France
11	*Corresponding Author : Unité des Virus Émergents (UVE) Méditerranée Infection, 19-21, Bd. Jean Moulin
12	13005 Marseille, Tel: +33(0)4 13 73 21 51, <u>nazli.ayhan@univ-amu.fr</u>
13	
14	Abstract
15	
16	Background: Toscana virus (TOSV) is a sandfly-borne phlebovirus causing central nervous system (CNS)
17	infection in Mediterranean countries, during summer season. However, clinical aspects of the disease
18	caused by this virus are poorly known by clinicians, so that its prevalence is probably underestimated
19	due to a lack of diagnosis.
20	Study design: We gathered data from all available case series and retrospective studies identifying
21	TOSV as the causative viral agent. The informations of age, sex, clinical characteristics, laboratory
22	findings, imaging results and clinical outcomes of TOSV infection were recorded and analyzed.
23	Results: In our review a total of 95 articles including TOSV infections resulting in a total of 1,381 cases
24	were analyzed. Our findings indicate, TOSV affects individuals across various age groups, with a median
25	age of 44.45 years. A notable disparity in infection rates between genders, with men being significantly
26	rNOTE: likie lyebon præseta besynraptor i bathæ no ballsæntlina hyvæn reviewaitha havsen i at ioserfo290 (politi 0:002) sticke

27	clinical presentation of TOSV infection encompasses a range of symptoms, including fever, headache,
28	retro-orbital pain, neurological and muscular manifestations with less common reports of cutaneous
29	and gastrointestinal symptoms. To date, six fatalities have been attributed to TOSV infections, with a
30	median age of 76 years.
31	Diagnostic evaluation of TOSV infections often involves the analysis of cerebrospinal fluid, where
32	findings may include an elevated white blood cell count.
33	Conclusions: These findings underscore the diverse clinical manifestations of TOSV infections and
34	highlight the importance of considering this pathogen in the differential diagnosis of patients
35	presenting with acute febrile illness, especially in endemic regions. TOSV represents an emerging
36	infectious threat that warrants inclusion in the diagnostic protocols for patients presenting with CNS,
37	particularly within the Mediterranean basin or for those with recent travel history to endemic regions
38	during warmer months when sandflies are actively circulating.
39	

41 Introduction


42 Toscana virus (TOSV) is classified within the Phlebovirus toscanaense species of the Phenuiviridae 43 family within the Bunyavirales order. TOSV is recognized as a significant human pathogen prevalent in 44 the Mediterranean region (1). Recent studies, including Medlock et al. (2) have documented a 45 concerning increase in the population density of blood-feeding insects, along with their dissemination 46 into territories previously considered free of sand flies. This expansion of the sand fly habitats 47 substantially increases the risk of TOSV exposure among human population. Cases of TOSV infection 48 have been reported in various Mediterranean countries such as; Italy, Spain, Portugal, France, Türkiye, 49 Croatia, Greece, Algeria, Tunisia (3). Seroprevalence studies in both human and non-human 50 vertebrates have revealed significant infection rates, with high prevalence reported in Italy (19.8%) (4), 51 Türkiye (17.8%) (5), Greece (21%) (6), North Africa (22%-41%) (7); and the Balkans (37.5%) (8) 52 indicating the widespread presence of TOSV across the Mediterranean basin. A recent retrospective 53 study in Germany by Dersch et al. (2021) identified cases of TOSV-neuroinvasive disease in patients 54 with meningoencephalitis with no recent travel history to endemic areas, suggesting a broader 55 geographical spread than previously thought (9). TOSV is listed in the first three viral agents causing 56 neurological infection at least in Italy, Spain and France together with enteroviruses and herpesviruses 57 during warm season (10). However, the rare inclusion of TOSV in the diagnostic algorithm of nervous 58 system infections (CNS) infections results in an important underestimation of the incidence (3). 59 The objective of our study was to review the available data about clinical characteristics of TOSV

60 infections to raise the awareness of physicians about this emerging pathogen.

61

63 Material and Method

- 64 Study design
- Relevant entries in global Web-based resources that comprise Scopus (http://www.scopus.com/), Web of Science (https://isiknowledge.com), and PubMed (https://pubmed.ncbi.nlm.nih.gov), Google scholar (https://scholar.google.com.tr/) were searched. Database investigations were performed using the keywords "bunyavirus", "phlebovirus,", "Toscana virus", "TOSV", "Toscana virus case report", "nervous system infection". Reports unrelated to TOSV infection were omitted, as well as conference reports with recurring data in publications. The references cited in each report were examined for further publications, which were included in the analysis (Figure 1).



72


Figure2. Toscana virus local and imported case distribution map.

74 Statistical Analysis

- 75 All variables (described in Table 1) were screened using a logistic regression univariate analysis to check
- for statistically significant associations of demographic characters with TOSV in SPSS version 24.
- 77 Results
- 78 Demographic and geographic characteristics

79 We conducted an inventory of 95 articles including 48 case reports, 32 case series and 15 retrospective 80 studies, documenting a total of 1,381 cases of TOSV infection cases between 1985 and 2023. Age and 81 sex demographics were obtained for 762 and 1,115 patients respectively (Table 1). Significantly more 82 male patients were reported with TOSV infection compared to female patients (744 males to 371 females; p<0.001). 83 TOSV infections were recorded in 12 countries: with the majority of cases originating from Italy 84 85 (n=1064), followed by Spain (n=76), Greece (n=45), Türkiye and Tunisia each with (n=31), France (n=27), Algeria (n=23), and lesser numbers from Croatia (n=12), Portugal (n=12), Romania (n=8), 86

- 87 Bosnia & Herzegovina (n=7), Germany (n=4) and Israel (n=1). A total of 40 travelers returning from
- 88 Mediterranean countries were reported, of which 30 had visited Italy, including both mainland and
- 89 islands (Figure2).





91 **Figure2.** Toscana virus local and imported case distribution map.

TOSV infections were reported across a wide range of age groups, with the youngest patient being between 0-5 year old (11) and the oldest between 90-95 year old (12); the median age of patients was 44.4 years. The disease manifested in 82 pediatric patients under 15 years of age, as documented in nine studies (11–19). Notably, the prevalence of TOSV infection in children was significantly lower, at 5.9%.

- 97 Clinical characteristics
- 98 Typical manifestations

99 Retro-orbital pain was the most common symptom (156/163, 95.7%). Then headache was observed in 100 93.2% of cases (566/607) sometimes reported as the "worst headache of their life". Fever was 101 described in 91.9% (678/738) of cases with an abrupt onset and temperature ranging from 38°C to 102 39.5°C. Neck rigidity was reported in 88.2% (473/536). Other non-specific signs such as

103 nausea/vomiting, muscle weakness, asthenia and fatigue were described in almost 80% of cases (Table

104 1).

105 **Table 1.** Demographic characteristics and non-specific clinical signs.

	Number of cases	Total	%
Age, median [range]	44.45	762	
Sex (male/female)	744/371	1115	
Signs			
Fever	678	738	91.9
Headache	566	607	93.2
Nausea/Vomiting	340	431	78.9
Neck rigidity	473	536	88.2
Muscle weakness / Asthenia / Fatigue	34	43	79.1
Retro-orbital pain	156	163	95.7

106 Neurological manifestations

107 Of the 644 documented cases, 519 patients (representing 80.6%) presented with meningitis or aseptic 108 meningitis, while 111 patients presented with either pure encephalitis or meningo-encephalitis (Table 109 2); myelitis was very rarely reported. Until recently, a total of 49 cases were recorded as 110 meningitis/meningo-encephalitis. More recently, Mellace et al. (2022) identified 331 cases featuring 111 neurological symptoms; however, the distinction between meningitis and 112 encephalitis/meningoencephalitis was not clearly defined.. As a consequence, although central manifestations are not unusual, pure meningitis is the most prominent neurological manifestation of 113 114 **TOSV** infections.

116 **Table 2. TOSV neurological manifestations.**

		Total	
	Number of cases	analysed	%
		cases	
Clinical Presentations			
Meningitis /Aseptic Meningitis	519	644	80.6
Encephalitis	77	241	32.0
Meningoencephalitis	34	221	15.4
Meningitis/Aseptic Meningitis or Meningoencephalitis	49		
Myelitis	2		
Total	684+331* = 1015	1382	73.44

117 * However recent article include 331 patients with meningitis, meningoencephalitis, encephalitis and polineuropatia didn't

included the number count due to lack of information for each clinical presentation but included in total count (19).

- 119 Three cases of hydrocephalus were documented in young patients (range between 15-25 year-old); in
- all cases, hydrocephalus was observed as a complication following viral meningoencephalitis (20,21).
- 121 Specific neurological manifestations were categorized based on their involvement of either the central
- 122 or peripheral nervous system, as detailed in Table 3.

123 Table 3. TOSV neurological signs and symptoms.

Neurological Manifestations:

signs and symptoms denoting a central nervous system involvement

abnormal behavior, agitation, anhedonia irritability, aphasia, ataxia, blurred vision, cerebral atrophy,

confusion, depression, double vision, dysmetria, epilepsy, facial paresis, focal neurological deficit,

hallucinations, hemiparesis/paresis, hydrocephalus, hypotonia, impaired consciousness, insomnia,

nystagmus, obtundation, occipital/ischemic stroke, paresis, paresthesia, phonophobia, photophobia,

kernig's sign, seizure, sleepiness, stumbling and dysmetria, tetra paresis, tonic-clonic seizure, tremor

signs and symptoms denoting a peripheral nervous system involvement

brachial plexitis, Guillain Barré like syndrome, hyperaesthesia, limited atrophy, motor ans sensory neuropathy, peripheral polyneuropathy,

124

- 125 Out of 712 patient, 569 exhibited at least one neurological signs or symptoms listed in Table3. Among 126 central neurological manifestations, Kernig's sign was the most prevalent, observed in 135 cases, 127 followed by decreased consciousness and photophobia (n=41), facial or leg hemiparesis /paresis (n=17) 128 and confusion (n=16). Speech impairmentwas reported in eight patients(22-28) while six patients 129 experienced hearing impairment, characterized by bilateral deafness that persisted beyond the acute 130 phase and 6 patients reported hearing impairment (29–32). Additionally, changes in personality, sexual 131 and social disinhibition, aggressiveness, and other abnormal behaviors were also documented (33,34) 132 (Table2). The presence of symptoms signing a peripheral neuropathy was observed in 14 cases of which 133 10 presented with Guillain-Barre like syndrome (35–37). 134 Ocular manifestations
- 135 Retro-orbital pain or pressure were very frequently observed, documented in 156 out of 163 cases. In
- 136 contrast, conjunctivitis was reported only in a single case (38) (Table4).

137 *Gastro-intestinal manifestations*

- 138 Gastro-intestinal manifestations consisting of gastroenteritis, abdominal pain, dysphagia or diarrhea
- 139 were reported rarely (16/43). (20,37,39–41) (Table4).

140 Cutaneous manifestations

Dermatological symptoms including petechiae, rash, exanthema, and febrile erythema were reported in 15 out of 38 cases. Rash was the most frequently observed symptom, noted in 11 cases (20,29,39,41–45) (46) (Table4).

144 Muscular manifestations

- 145 The musculoskeletal symptoms observed included cramps, myalgia/arthralgia, myositis/fasciitis, and
- 146 muscle stiffness. Among the 51 patients who exhibited these symptoms, all presented with myalgia
- 147 and/or arthralgia (12,18,22,35,38,44,45,47–53) (Table4).

148 Table 4. Number of TOSV cases with muscular, ocular, gastro-intestinal, cutaneous and

149 neurological manifestations.

	Number of cases	Total	%
Muscular Manifestations	51	211	24,2
Myalgia / Arthralgia	51	211	24,2
Ocular Manifestations	157	164	95,7
Retroorbital pain or pressure	156	163	95,7
Gastro-intestinal Manifestations	16	43	37,2
Gastroenteritis	7	16	43,8
Cutaneous Manifestations	15	38	39,5
Rash	11	32	34,4
Neurological Manifestations	569	712	79.9
Central Nervous System Manifestations	560	683	82
Peripheral Nervous System Manifestations	14	26	53,8

150

151 *Testicular manifestations*

Testicular manifestations, including epididymo-orchitis, testicular pain, and swelling, were reported in
five patients (20,39,41,54,55) (Table 5). These symptoms were significantly more frequent (p-value
<0.001) among younger patients, with a median age of 27 years (range 16-44) (Table 5). Recently, TOSV
RNA was detected in the seminal fluid of a patient in the age range of 20-25 year old until day 59 after
infection without any testicular manifestations (28).

157 **Table 5.** TOSV infection cases with testicular manifestations.

Characteristic / References	Age range / Age	Fever	Headache	Neck rigidity /	Nausea /
	median [range] (n)	rever	neuddene	pain	vomiting
Echevarria et al. 2003	25-29	NR*	NR*	NR*	NR*
Baldelli et al. 2004	15-19	1	1	1	1
Zanelli et al. 2013	25-29	1	1	-	-
Tschumi et al. 2019	20-24	1	1	-	-
Mascitti et al. 2020	40-44	1	1	-	-
	27 [16-44] (5)	4	4	1	1

158 *, NR, not reported

159 Severe cases and Mortality

160 Although TOSV infections are frequently associated with severe clinical manifestations, the vast 161 majority of patients recover completely. Nonetheless, six fatal cases have been reported across two 162 studies: the first fatality occurred in Italy (31); and five subsequent fatalities were reported in Romania 163 (31,49). The overall the mortality rate is 0.43% with deceased patients having a median age of 76 yearsold (range 70-91). Age was found to have a statistically significant impact on mortality (*p*-value < 0.001). 164 165 In addition, five out of six fatal cases had comorbidities such as hypertension and diabetes (Table6). 166 There were nine cases of severe TOSV infections leading to coma (20,31,49,56). Seven of these were 167 elder patients with median age of 79, six of whom had comorbidities such as diabetes and hypertension 168 and two patients were two siblings with the age range between 15 to 20, previously mentioned as 169 having developed hydrocephalus following infection.

- 170
- 171
- 172
- 173

174 Table6. TOSV infection lethal cases.

Reference	Nb of case	Sex	Age Range	Country	Comorbidities	Period	In-hospital lengt of stay (days)
Bartels et al. 2012	1	male	70-74	Italy	-	-	14
					Hypertension, congestive		
	1	1 male 90-94 Romania	Romania	heart failure, ischemic heart disease, stroke	June	10	
					sequelae		
					Hypertension, diabetes		
	1	female	65-69	Romania	mellitus, obesity,	August	4
					NonHodgkin lymphoma		
	1 male 75-79 Roman	Romania	Diabetes mellitus type II,	August	19		
Popescu et al. 2021	Ţ	male	e 75-79 Romai	Komama	Ischemic heart disease	August	15
					Diabetes mellitus type II,		
				Ischemic heart disease,			
	1	mala	70 74	_ .	Atrial fibrillation,	August	4
	1	male	70-74	Romania	Congestive heart failure,		
			Diabetic polyneuropathy				
			and arteriopathy				
					Hypertension, Stroke		
	1 female 85-89 Romani	Romania	sequelae, Chronic renal	August	6		
					failure		

175

176

177 *Laboratory characteristics*

178 Cerebrospinal fluid (CSF) analysis showed elevated white blood cell (WBC) levels in 22 cases.

179 Lymphocytic predominance ratio was high in 82% of the patients (47 out of 57) (>50%). CSF samples

180 showed high protein levels in 102 patients. Mildly elevated glucose levels have been showed in 179

181 patients (Table 7).

Table 7. TOSV laboratory characteristics.

		Normal		
Laboratory Findings	Mean (n) [range]	range/percentage		
CSF protein level (mg/dL)	56.34 (77) [11-757]	15-45		
CSF WBC (cells/mm3)	432.50 (22) [6-3500]	0-5		
CSF Lymphocytes ratio (%)	73.40% (57) [18%-100%]	50%		
CSF Glucose (mg/dL)	63.21 (60) [29-132]	>40		

183

184 Electro-physiology analysis

185 The electroencephalogram (EEG) showed abnormal results in 43 patients (11,23,31,56–62) with non-

186 specific abnormalities, occasional spikes and slow waves (58).

187 Imaging and Radiological findings and electrocardiogram tests

188 When available, magnetic resonance imaging (MRI) results showed diffuse encephalopathy, diffuse

atrophy abnormalities, diffuse bilateral asymmetric myositis or scattered punctuate T2-hyperintense

190 non-enhancing white matter lesions in 11 patients (21,27,45,53,63). Cerebral atrophy and/or occipital

191 stroke sequelae were detected in 2 patients with computerized tomography (CT) scan (49).

192 Few patients were examined by with electrocardiogram (ECG) and chest X-ray. Chest X-ray 193 demonstrated an opacity in the right middle lobe of the lung of one patient (29). No abnormalities

194 were recorded with ECG after TOSV infection (Table8).

195

196

198

199

200 Table8. TOSV electro-physiology analysis and radiology findings.

Electro-physiology analysis and radiology findings	Number of abnormal cases	Total
EEG	43	82
MRI	11	30
СТ	3	30
Chest X-ray	1	8
ECG	0	3

201

202 Discussion

Infections caused by TOSV exhibit a high diversity of clinical manifestations, none of them being neither pathognomonic nor highly specific. It is crucial to provide a comprehensive analysis of the observed signs in order to improve the clinical orientation for physicians seeing both residents and visitors in the Mediterranean regions during the warm season when TOSV can be transmitted by sand flies (Figure 1). Unlike other neuroinvasive viruses such as herpes viruses and enteroviruses, TOSV infections occur exclusively during the period of activity of phlebotomine sand flies, typically from March to November in the Mediterranean, with slight variations depending on local climate conditions (64).

From 1985 to2023, a total of 1,381 cases were reported from 12 different countries of which the majority (1,064 cases, 77%) occurred in Italy. The annual incidence rate of cases fluctuates considerably in relation with complex biology of vectors, hosts and environmental factors. TOSV infections have been documented across a broad age spectrum (median age 44.45 years, ranging from 0 to 95 years old); however, age itself is not indicative of etiology, though most cases occur between 20 and 60 years old. Using data collected in travelers returning to their homeland, the median incubation period was calculated at 12 days (10-14 days) for the neuroinvasive forms (65). Whether the same incubation
 period applies for milder cases remains unexplored.

TOSV symptomatic infections are observed twice as frequently in males as in females. The reasons for this gender disparity in symptomatology could be related to differences in immune response, viral susceptibility, or possibly due to variations in exposure factors and the prevalence of high-risk behaviors. However, similar seroprevalence rates between males and females suggest that behavioral factors alone may not explain this difference (66). Interestingly, the same tendency is also observed for WNV infections (67).

Both length of hospitalization and symptoms duration vary significantly based on the severity of the case. The longest hospitalization was 60 days (68) and the longest symptoms duration was 28 days (52,69). The letality rate of TOSV infections is 0.43% which is lower than other neuroinvasive arboviruses such as WNV, Japanese encephalitis virus (JEV) or tick-borne encephalitis virus (TBEV). All the fatal cases were older than 60 year-old; five of the six fatal cases had comorbidities such as hypertension and/or diabetes mellitus.

Severe neuroinvasive forms, characterized by encephalitis or meningo-encephalitis, are reported in 15.8 to 32.0% of neurological cases, the latter representing almost 80% of 712 studied cases. Since TOSV cases reported in the literature are the most severe ones, neuroinvasive forms are certainly overrepresented. Common forms are frequent although they are likely to remain either undetected or unpublished (70); those forms are associated with unspecific clinical manifestations such as fever, headache, nausea, vomiting, retro-orbital pain and muscle weakness.

Severe long-lasting or permanent neurological sequelae such as consciousness impairment, hydrocephalus, ischemic stroke and aphasia (20,49,68,71,72) were described. In contrast with other arboviruses, severe neurological forms are not more frequent in the elderly (19). However, the lower incidence rate of TOSV infections in the pediatric group (5.9%) can either be explained by a lower exposure and/or by a reporting bias, or by biological factors such as immune response and/or viral susceptibility.

```
242
```

Among system specific manifestations, CNS signs are the most frequently observed with 79.9% of cases 243 244 followed by ocular and muscular manifestations. Peripheral neurological manifestations, gastro-245 intestinal and cutaneous manifestations were reported rarely. Additionally, a unique case involved a 246 patient with gastrointestinal manifestations who was also co-infected with West Nile virus (37). 247 Although testicular manifestations are noteworthy, they have been documented in only five patients. 248 To date, aside from the Zika virus (ZIKV), no other arbovirus has been identified as a causative agent 249 for testicular manifestations. Recently, the presence and persistence of TOSV RNA in seminal fluid has 250 been demonstrated without evidence for sexual transmission (28).

In most of cases presenting with clinical picture justifying CSF collection, CSF was clear and colorless.
The CSF formula showed elevated WBC levels in 22 patients and lymphocytic meningitis in 58 patients.
Mildly elevated protein and glucose levels were described in 102 patients and 179 patients
respectively. Hypoglycorachia was never reported. CSF parameters were available only for a subset of
the reviewed cases.

Electro-physiology analysis and radiology findings showed abnormalities in EEG or in MRI for 56 cases
(4%). CT scan and chest X-ray were performed occasionally and abnormalities were rarely recorded.
No abnormalities were recorded for ECG which was performed only for three patients (58,73,74)

In almost all cases, the recovery is complete without persisting functional sequelae. However, there are a few documented cases where individuals have experienced complicated forms of meningitis and/or encephalitis with lingering effects attributed to TOSV. These effects include impaired cognitive functions and altered social and sexual behaviors (60,68) Other neuroinvasive arboviruses, such as WNV, JEV or TBEV, cause long-lasting or permanent sequelae (75).

Finally, most TOSV infections remain undiagnosed, as TOSV is not included in the list of pathogens to be screened in patients presenting with febrile illness and/or neurological manifestations in areas where the virus is endemic. The only exception is Italy where it is recommended to include TOSV in the panel of viruses to be tested during summertime for suspect cases. This is likely why most cases are reported in Italy besides the fact that TOSV has been discovered in Italy and that physicians are much more aware of its existence than in other at risk countries. This oversight is highlighted by numerous retrospective studies, which suggest that many cases of TOSV infection are classified as "infections due to unknown pathogenic agents" due to the absence of specific laboratory screening for TOSV (35,51,76,77). Nevertheless, most TOSV cases exhibit nonspecific signs or symptoms with short duration in non-severe cases.

Together, the combination of lack of awareness of physician with absence of recommendations to screen suspect cases using specific laboratory tests has and continue to greatly contribute to the underestimation of TOSV cases despite its public health importance.

277

278

279 Acknowledgement

280

281 This study was funded by European Commission grant 101057690 and UKRI grants 10038150 and 282 10039289, and is catalogued by the CLIMOS Scientific Committee as CLIMOS number XXXX* (http:// 283 www.climos-project.eu). The contents of this publication are the sole responsibility of the authors and 284 do not necessarily reflect the views of the European Commission, the Health, and Digital Executive 285 Agency, or UKRI. Neither the European Union nor granting authority nor UKRI can be held responsible. 286 The funders had no role in study design, data collection and analysis, decision to publish, or preparation 287 of the manuscript. For the purposes of Open Access, the authors have applied a CC BY [option: CC BY-288 ND] public copyright license to any Author Accepted Manuscript version arising from this submission. 289 CLIMOS forms part of the Climate Change and Health Cluster comprising six Horizon Europe projects: 290 BlueAdapt, CATALYSE, CLIMOS, HIGH Horizons, IDAlert, and TRIGGER. 291 *The number will be added after publication.

293 References

294	1.	Charrel RN, Bichaud L, de Lamballerie X. Emergence of Toscana virus in the mediterranear
-----	----	--

- 295 area. World J Virol . 2012;1(5):135–41. DOI: https://doi.org/10.5501/wjv.v1.i5.135
- 296 2. Medlock JM, Hansford KM, Van Bortel W, Zeller H, Alten B. A summary of the evidence for the
- 297 change in European distribution of phlebotomine sand flies (Diptera: Psychodidae) of public
- health importance. J Vector Ecol. 2014:72–7. DOI: https://doi.org/10.1111/j.1948-
- 299 7134.2014.12072.x
- 300 3. Ayhan N, Charrel RN. An update on Toscana virus distribution, genetics, medical and
- 301 diagnostic aspects. Clin Microbiol Infect. 2020;26(8). DOI:
- 302 https://doi.org/10.1016/j.cmi.2019.12.015
- 303 4. Terrosi C, Olivieri R, Bianco C, Cellesi C, Cusi MG. Age-dependent seroprevalence of Toscana
- 304 virus in central Italy and correlation with the clinical profile. Clin Vaccine Immunol.
- 305 2009;16(8):1251–2. DOI: https://doi.org/ 10.1128/CVI.00376-08
- 306 5. Ergunay K, Aydogan S, Ilhami Ozcebe O, Cilek EE, Hacioglu S, Karakaya J, et al. Toscana Virus
- 307 (TOSV) exposure is confirmed in blood donors from Central, North and South/Southeast
- 308 Anatolia, Turkey. Zoonoses Public Health . 2012;59(2):148–54. DOI:
- 309 https://doi.org/10.1111/j.1863-2378.2011.01436.x
- 310 6. Anagnostou V, Papa A. Seroprevalence of Toscana virus among residents of Aegean Sea
- 311 islands, Greece. Travel Med Infect Dis . 2013;11(2):98–102. DOI:
- 312 https://doi.org/10.1016/j.tmaid.2012.11.006
- 313 7. Alkan C, Allal-Ikhlef AB, Alwassouf S, Baklouti A, Piorkowski G, de Lamballerie X, et al. Virus
- 314 isolation, genetic characterization and seroprevalence of Toscana virus in Algeria. Clin
- 315 Microbiol Infect . 2015;21(11):1040.e1-1040.e1. DOI:
- 316 https://doi.org/10.1016/j.cmi.2015.07.012
- 8. Punda-Polic V, Jeroncic A, Mohar B, Kraljevic KS. Prevalence of Toscana virus antibodies in
- 318 residents of Croatia. Clin Microbiol Infect. 2012;18(6):200–3. DOI:

319 https://doi.org/10.1111/j.1469-0691.2012.03840.x

- 320 9. Dersch R, Sophocleous A, Cadar D, Emmerich P, Schmidt-Chanasit J, Rauer S. Toscana virus
- 321 encephalitis in Southwest Germany: a retrospective study. BMC Neurol . 2021;21(1):1–5. DOI:
- 322 https://doi.org/10.1186/s12883-021-02528-7
- 323 10. Gori Savellini G, Gandolfo C, Cusi MG. Epidemiology of Toscana virus in South Tuscany over
- 324 the years 2011-2019. J Clin Virol. 2020;128:104452. DOI:
- 325 https://doi.org/10.1016/j.jcv.2020.104452
- 326 11. Braito A, Ciufolini MG, Pippi L, Corbisiero R, Fiorentini C, Gistri A, et al. Phlebotomus-
- 327 transmitted toscana virus infections of the central nervous system: a seven-year experience in
- 328 Tuscany. Scand J Infect Dis . 1998;30(5):505–8. DOI:
- 329 https://doi.org/10.1080/00365549850161539
- 330 12. Papa A, Kontana A, Tsergouli K. Phlebovirus infections in Greece. J Med Virol .
- 331 2015;87(7):1072–6. DOI: https://doi.org/10.1002/jmv.24163
- 13. Mendoza-Montero J, Gamez-Rueda M-I, Navarro-Mari J-M, de la Rosa-Fraile M, Oyonarte-
- 333 Gomez S. Infections Due to Sandfly Fever Virus Serotype Toscana in Spain. Clin Infect Dis .
- 334 1998;27(3):434–6. DOI: https://doi.org/10.1086/514684
- 335 14. Braito A, Corbisiero R, Corradini S, Fiorentini C, Ciufolini MG. Toscana virus infections of the
- 336 central nervous system in children: A report of 14 cases. J Pediatr . 1998;132(1):144–8. DOI:
- 337 https://doi.org/10.1016/S0022-3476(98)70500-1
- 338 15. Santos L, Simões J, Costa R, Martins S, Lecour H. Toscana virus meningitis in Portugal, 2002-
- 339 2005. Euro Surveill . 2007;12(6):E3-4. DOI: https://doi.org/10.2807/esm.12.06.00715-en
- 16. Anagnostou V, Pardalos G, Athanasiou-Metaxa M, Papa A. Novel phlebovirus in febrile child,
- 341 Greece. Emerg Infect Dis . 2011;17(5):940–1. DOI: https://doi.org/ 10.3201/eid1705.101958
- 17. Punda-Polić V, Mohar B, Duh D, Bradarić N, Korva M, Fajs L, et al. Evidence of an
- 343 autochthonous Toscana virus strain in Croatia. J Clin Virol . 2012;55(1):4–7. DOI:
- 344 https://doi.org/10.1016/j.jcv.2012.06.006

- 18. Dupouey J, Bichaud L, Ninove L, Zandotti C, Thirion-Perrier L, de Lamballerie X, et al. Toscana
- 346 virus infections: A case series from France. J Infect . 2014;68(3):290–5. DOI:
- 347 https://doi.org/10.1016/j.jinf.2013.11.006
- 19. Mellace F, Del Manso M, Oradini-Alacreu A, Ceccarelli E, Mateo-Urdiales A, Petrone D, et al.
- 349 Meningiti, meningo-encefaliti ed encefaliti da virus Toscana in Italia, 2016-2021. Punta
- dell'iceberg di una arbovirosi endemica poco conosciuta. Boll Epidemiol Naz . 2024;3(2):10–9.
- 351 20. Baldelli F, Grazia Ciufolini M, Francisci D, Marchi A, Venturi G, Fiorentini C, et al. Unusual
- 352 Presentation of Life-Threatening Toscana Virus Meningoencephalitis. Clin Infect Dis .
- 353 2004;38(4):515–20. DOI: https://doi.org/10.1086/381201
- 354 21. Oechtering J, Petzold GC. Acute hydrocephalus due to impaired CSF resorption in Toscana
- 355 virus meningoencephalitis. Neurology . 2012;79(8):829–31. DOI:
- 356 https://doi.org/10.1212/WNL.0b013e3182661f1
- Calisher CH, Weinberg AN, Muth DJ, Lazuick JS. Toscana virus infection in United States citizen
 returning from Italy. Lancet (London, England) . 1987;1(8525):165–6. DOI:
- 359 23. Epelboin L, Hausfater P, Schuffenecker I, Riou B, Zeller H, Bricaire F, et al. Meningoencephalitis
- 360 Due to Toscana Virus in a French Traveler Returning From Central Italy. J Travel Med .
- 361 2008;15(5):361–3. DOI: https://doi.org/10.1111/j.1708-8305.2008.00221.x
- 362 24. Sanbonmatsu-Gámez S, Pérez-Ruiz M, Collao X, Sánchez-Seco MP, Morillas-Márquez F, de la
- 363 Rosa-Fraile M, et al. Toscana virus in Spain. Emerg Infect Dis . 2005;11(11):1701–7. DOI:
- 364 https://doi.org/ 10.3201/eid1111.050851
- 365 25. Kay MK, Gibney KB, Riedo FX, Kosoy OL, Lanciotti RS, Lambert AJ. Toscana virus infection in
- 366 American traveler returning from Sicily, 2009. Emerg Infect Dis . 2010;16(9):1498–500. DOI:
- 367 https://doi.org/ 10.3201/eid1609.100505
- 368 26. Greco F, Mauro MV, Tenuta R, Apuzzo G, Giraldi C. A new case of meningitis due to Toscana
 369 virus . Vol. 35, NEW MICROBIOLOGICA. 2012; 1:35(1):99.
- 370 27. Suardi LR, Di Lauria N, Pozzi M, Rogasi PG, Barilaro A, Azzolini F, et al. Acute cerebellar ataxia:

- a rare Toscana Virus (TOSV) meningoencephalitis complication. 2019;130(3):276–8. DOI:
- 372 https://doi.org/10.1080/00207454.2019.1673748
- 28. Matusali G, D'Abramo A, Terrosi C, Carletti F, Colavita F, Vairo F, et al. Infectious Toscana Virus
- in Seminal Fluid of Young Man Returning from Elba Island, Italy. Emerg Infect Dis .
- 375 2022;28(4):865. DOI: https://doi.org/ 10.3201/eid2804.211920
- 29. Howell BA, Azar MM, Landry ML, Shaw AC. Toscana virus encephalitis in a traveler returning
- to the United States. J Clin Microbiol . 2015;53(4):1445–7. DOI: https://doi.org/
- 378 10.1128/JCM.03498-14
- 379 30. Ocal M, Orsten S, Inkaya AC, Yetim E, Acar NP, Alp S, et al. Ongoing Activity of Toscana Virus
- 380 Genotype A and West Nile Virus Lineage 1 Strains in Turkey: A Clinical and Field Survey.
- 381 Zoonoses Public Health . 2014;61(7):480–91. DOI: https://doi.org/10.1111/zph.12096
- 382 31. Bartels S, Boni L, Kretzschmar HA, Heckmann JG. Lethal encephalitis caused by the Toscana
- 383 virus in an elderly patient. J Neurol . 2012;259(1):175–7. DOI:
- 384 https://doi.org/10.1007/s00415-011-6121-y
- 385 32. Martínez-García FA, Moreno-Docón A, Segovia-Hernández M, Fernández-Barreiro A.
- 386 [Deafness as a sequela of Toscana virus meningitis]. Med Clin (Barc) . 2008;130(16):639. DOI:
- 387 https://doi.org/10.1157/13120347
- 388 33. Osborne JC, Khatamzas E, Misbahuddin A, Hart R, Sivaramakrishnan A, Breen DP. Toscana
- 389 virus encephalitis following a holiday in Sicily. Pract Neurol . 2016;16(2):139–41. DOI:

390 https://doi.org/10.1136/practneurol-2015-001265

- 391 34. Serata D, Rapinesi C, Del Casale A, Simonetti A, Mazzarini L, Ambrosi E, et al. Personality
- 392 Changes After Toscana Virus (TOSV) Encephalitis in a 49-Year-Old Man: A Case Report. Int J
- 393 Neurosci . 2011;121(3):165–9. DOI: https://doi.org/10.3109/00207454.2010.537412
- 394 35. Ocal M, Orsten S, Inkaya AC, Yetim E, Acar NP, Alp S, et al. Ongoing Activity of Toscana Virus
- 395 Genotype A and West Nile Virus Lineage 1 Strains in Turkey: A Clinical and Field Survey.
- 396 Zoonoses Public Health . 2014;61(7):480–91. DOI: https://doi.org/10.1111/zph.12096

- 397 36. Rota E, Morelli N, Immovilli P, De Mitri P, Guidetti D. Guillain-Barré-like axonal
- 398 polyneuropathy associated with Toscana virus infection: A case report. Medicine (Baltimore).
- 399 2017;96(38):e8081. DOI: https://doi.org/10.1097/MD.000000000008081
- 400 37. Okar SV, Bekircan-Kurt CE, Hacıoğlu S, Erdem-Özdamar S, Özkul A, Ergünay K. Toscana virus
- 401 associated with Guillain–Barré syndrome: a case–control study. Acta Neurol Belgica 2020
- 402 1213 . 2020;121(3):661–8. DOI: https://doi.org/10.1007/s13760-020-01279-5
- 403 38. Tappe D, Schmidt-Chanasit J, Günther S, Ries A, Ziegler U, Müller A, et al. Acute Toscana virus
- 404 infection mimicked by Yersinia-induced reactive arthritis syndrome after journey to Spain. J
- 405 Clin Virol. 2010;47(1):104–5.
- 406 39. Echevarría J-M, de Ory F, Guisasola M-E, Sánchez-Seco M-P, Tenorio A, Lozano Á, et al. Acute
- 407 meningitis due to Toscana virus infection among patients from both the Spanish
- 408 Mediterranean region and the region of Madrid. J Clin Virol . 2003;26(1):79–84. DOI:
- 409 https://doi.org/10.1016/S1386-6532(02)00041-0
- 410 40. Anagnostou V, Pardalos G, Athanasiou-Metaxa M, Papa A. Novel phlebovirus in febrile child,
- 411 Greece. Emerg Infect Dis . 2011;17(5):940–1. DOI: https://doi.org/ 10.3201/eid1705.101958
- 412 41. Zanelli G, Bianco C, Cusi MG. Testicular involvement during Toscana virus infection: an
- 413 unusual manifestation? Infection . 2013;41(3):735–6. DOI: https://doi.org/10.1007/s15010-
- 414 012-0368-9
- 415 42. Schultze D, Korte W, Rafeiner P, Niedrig M. First report of sandfly fever virus infection
- 416 imported from Malta into Switzerland, October 2011. Euro Surveill . 201;17(27). DOI:
- 417 https://doi.org/10.2807/ese.17.27.20209-en
- 418 43. Arden KE, Heney C, Shaban B, Nimmo GR, Nissen MD, Sloots TP, et al. Detection of Toscana
- 419 virus from an adult traveler returning to Australia with encephalitis. J Med Virol .
- 420 2017;89(10):1861–4. DOI: https://doi.org/10.1002/jmv.24839
- 421 44. Dominati A, Sap L, Vora S. [Fever in a returning traveler from Tuscany]. Rev Med Suisse .
- 422 2018;14(592):294–6.

- 423 45. Vilibic-Cavlek T, Zidovec-Lepej S, Ledina D, Knezevic S, Savic V, Tabain I, et al. Clinical,
- 424 Virological, and Immunological Findings in Patients with Toscana Neuroinvasive Disease in
- 425 Croatia: Report of Three Cases. Trop Med Infect Dis 2020, Vol 5, Page 144 . 2020;5(3):144.
- 426 DOI: https://doi.org/10.3390/tropicalmed5030144
- 427 46. Gámbaro F, Pérez AB, Prot M, Agöera E, Baidaliuk A, Sánchez-Seco MP, et al. Untargeted
- 428 metagenomic sequencing identifies Toscana virus in patients with idiopathic meningitis,
- 429 southern Spain, 2015 to 2019. Eurosurveillance. 2023;28(45):2200913. DOI:
- 430 https://doi.org/10.2807/1560-7917.ES.2023.28.45.2200913
- 431 47. Nicoletti L, Renzi A, Caciolli S, Nicoletti L, Bartolozzi D, Balducci M, et al. Central Nervous
- 432 System Involvement during Infection by Phlebovirus Toscana of Residents in Natural Foci in
- 433 Central Italy (1977–1988). Am J Trop Med Hyg . 1991;45(4):429–34. DOI:
- 434 https://doi.org/10.4269/ajtmh.1991.45.429
- 435 48. Pauli C, Schwarz TF, Meyer CG, Jager G. [Neurological symptoms after an infection by the
- 436 sandfly fever virus]. Dtsch Med Wochenschr . 1995;120(43):1468–72. DOI:
- 437 https://doi.org/10.1055/s-2008-1055501
- 438 49. Mosnier E, Charrel R, Vidal B, Ninove L, Schleinitz N, Harlé JR, et al. Toscana virus myositis and
- 439 fasciitis. Med Mal Infect . 2013;43(5):208–10. DOI:
- 440 https://doi.org/10.1016/j.medmal.2013.04.002
- 441 50. Erdem H, Ergunay K, Yilmaz A, Naz H, Akata F, Inan AS, et al. Emergence and co-infections of
- 442 West Nile virus and Toscana virus in Eastern Thrace, Turkey. Clin Microbiol Infect .
- 443 2014;20(4):319–25. DOI: https://doi.org/10.1111/1469-0691.12310
- 444 51. Schirmer L, Wölfel S, Georgi E, Ploner M, Bauer B, Hemmer B. Extensive Recruitment of
- 445 Plasma Blasts to the Cerebrospinal Fluid in Toscana Virus Encephalitis. Open Forum Infect Dis .
- 446 2015;2(3):ofv124. DOI: https://doi.org/10.1093/ofid/ofv124
- 447 52. Popescu CP, Cotar AI, Dinu S, Zaharia M, Tardei G, Ceausu E, et al. Emergence of Toscana
- 448 Virus, Romania, 2017–2018. Emerg Infect Dis . 2021;27(5):1482. DOI: https://doi.org/

449 10.3201/eid2705.204598

- 450 53. Quattrone F, Mazzetti P, Aquino F, Sani S, Carneglia L, Pistello M, et al. Two clusters of
- 451 Toscana virus meningo-encephalitis in Livorno Province and Elba Island, July-September 2018.
- 452 Ann Ig . 2020;32(6):674–81. DOI: https://doi.org/10.7416/ai.2020.2387
- 453 54. Tschumi F, Schmutz S, Kufner V, Heider M, Pigny F, Schreiner B, et al. Meningitis and
- 454 epididymitis caused by Toscana virus infection imported to Switzerland diagnosed by
- 455 metagenomic sequencing: A case report. BMC Infect Dis. 2019;19(1). DOI:
- 456 https://doi.org/10.1186/s12879-019-4231-9
- 457 55. Mascitti H, Calin R, Dinh A, Makhloufi S, Davido B. Testicular pain associated with clear fluid
- 458 meningitis: How many cases of Toscana virus are we missing? Int J Infect Dis. 2020;1:93:198–
- 459 200. DOI: https://doi.org/10.1016/j.ijid.2020.02.008
- 460 56. Kuhn J, Bewermeyer H, Hartmann-Klosterkoetter U, Emmerich P, Schilling S, Valassina M.
- 461 Toscana virus causing severe meningoencephalitis in an elderly traveller. J Neurol Neurosurg

462 Psychiatry . 2005;76(11):1605–6. DOI: https://doi.org/10.1136/jnnp.2004.060863

- 463 57. Braito A, Corbisiero R, Corradini S, Marchi B, Sancasciani N, Fiorentini C, et al. Evidence of
- 464 Toscana virus infections without central nervous system involvement: A serological study. Eur
- 465 J Epidemiol . 1997;13(7):761–4. DOI: https://doi.org/10.1023/A:1007422103992
- 466 58. Dionisio D, Valassina M, Ciufolini MG, Vivarelli A, Esperti F, Cusi MG, et al. Encephalitis
- 467 without Meningitis Due to Sandfly Fever Virus Serotype Toscana. Clin Infect Dis .
- 468 2001;32(8):1241–3. DOI: https://doi.org/10.1086/319759
- 469 59. Gabriel M, Resch C, Günther S, Schmidt-Chanasit J. Toscana virus infection imported from Elba
- 470 into Switzerland. Emerg Infect Dis . 2010;16(6):1034–6. DOI: https://doi.org/
- 471 10.3201/eid1606.091763
- 472 60. Serata D, Rapinesi C, Del Casale A, Simonetti A, Mazzarini L, Ambrosi E, et al. Personality
- 473 Changes After Toscana Virus (TOSV) Encephalitis in a 49-Year-Old Man: A Case Report. Int J
- 474 Neurosci . 2011;121(3):165–9. DOI: https://doi.org/10.3109/00207454.2010.537412

- 475 61. Nicuolo G Di, Pagliano P, Battisti S, Starace M, Mininni V, Attanasio V, et al. Toscana Virus
- 476 Central Nervous System Infections in Southern Italy. J Clin Microbiol . 2005;43(12):6186–8.
- 477 DOI: https://doi.org/10.1128/JCM.43.12.6186-6188.2005
- 478 62. Doudier B, Ninove L, Million M, de Lamballerie X, Charrel RN, Brouqui P. Unusual Toscana
- 479 virus encephalitis in southern France. Med Mal Infect . 2011;1(41):50–1. DOI: https://doi.org/
- 480 10.1016/j.medmal.2010.09.006
- 481 63. Marlinge M, Crespy L, Zandotti C, Piorkowski G, Kaphan E, Charrel RN, et al. A febrile
- 482 meningoencephalitis with transient central facial paralysis due to Toscana virus infection,
- 483 south-eastern France, 2014. Eurosurveillance. 2014; 4;19(48):20974. DOI:
- 484 https://doi.org/10.2807/1560-7917.ES2014.19.48.20974
- 485 64. Jaijakul S, Arias CA, Hossain M, Arduino RC, Wootton SH, Hasbun R. Toscana
- 486 meningoencephalitis: A comparison to other viral central nervous system infections. J Clin
- 487 Virol . 2012;55(3):204–8. DOI: https://doi.org/10.1016/j.jcv.2012.07.007
- 488 65. Laroche L, Jourdain F, Ayhan N, Bañuls AL, Charrel R, Prudhomme J. Incubation Period for
- 489 Neuroinvasive Toscana Virus Infections. Emerg Infect Dis . 2021;27(12):3147. DOI:
- 490 https://doi.org/10.3201/eid2712.203172
- 491 66. Masse S, Ayhan N, Capai L, Bosseur F, de Lamballerie X, Charrel R, et al. Circulation of Toscana
- 492 Virus in a Sample Population of Corsica, France. Viruses. 2019;11(9):817. DOI:
- 493 https://doi.org/10.3390/v11090817
- 494 67. McDonald E, Mathis S, Martin SW, Erin Staples J, Fischer M, Lindsey NP. Surveillance for West
- 495 Nile Virus Disease United States, 2009–2018. MMWR Surveill Summ. 2021;70(1):1–15. DOI:
- 496 http://dx.doi.org/10.15585/mmwr.ss7001a1
- 497 68. Sanbonmatsu-Gámez S, Pérez-Ruiz M, Palop-Borrás B, Navarro-Marí JM. Unusual
- 498 manifestation of toscana virus infection, Spain. Emerg Infect Dis . 2009;15(2):347–8. DOI:
- 499 https://doi.org/10.3201/eid1502.081001
- 500 69. Schwarz TF, Jager G, Gilch S, Pauli C. Serosurvey and laboratory diagnosis of imported sandfly

- 501 fever virus, serotype Toscana, infection in Germany. Epidemiol Infect . 1995;114:501–10. DOI:
- 502 https://doi.org/10.1017/ S0950268800052213
- 503 70. Hemmersbach-Miller M, Parola P, Charrel RN, Paul Durand J, Brouqui P. Sandfly fever due to
- 504 Toscana virus: an emerging infection in southern France. Eur J Intern Med. 2004 1;15(5):316–
- 505 7. DOI: https://doi.org/10.1016/j.ejim.2004.05.006
- 506 71. Kuhn J, Bewermeyer H, Hartmann-Klosterkoetter U, Emmerich P, Schilling S, Valassina M.
- 507 Toscana virus causing severe meningoencephalitis in an elderly traveller. J Neurol Neurosurg
- 508 Psychiatry . 2005;76(11):1605–6. DOI: https://doi.org/10.1136/jnnp. 2004.060863
- 509 72. Oechtering J, Petzold GC. Acute hydrocephalus due to impaired CSF resorption in Toscana
- 510 virus meningoencephalitis. Neurology . 2012;79(8):829–31. DOI:
- 511 https://doi.org/10.1212/WNL.0b013e3182661f1a
- 512 73. Epelboin L, Hausfater P, Schuffenecker I, Riou B, Zeller H, Bricaire F, et al. Meningoencephalitis
- 513 Due to Toscana Virus in a French Traveler Returning From Central Italy. J Travel Med .

514 2008;15(5):361–3. DOI: https://doi.org/10.1111/j.1708-8305.2008. 00221.x

- 515 74. Zanelli G, Bianco C, Cusi MG. Testicular involvement during Toscana virus infection: an
- 516 unusual manifestation? Infection . 2013;41(3):735–6. DOI: https://doi.org/10.1007/s15010-
- 517 012-0368-9
- 518 75. Kvam KA, Stahl JP, Chow FC, Soldatos A, Tattevin P, Sejvar J, et al. Outcome and Sequelae of
 519 Infectious Encephalitis. J Clin Neurol . 2024;20(1):23. DOI: https://doi.org/10.3988/jcn.
- 520 2023.0240
- 521 76. Francisci D, Papili R, Camanni G, Morosi S, Ferracchiato N, Valente M, et al. Evidence of
- 522 Toscana virus circulation in Umbria: First report. Eur J Epidemiol. 2003;18(5):457–9. DOI:
- 523 https://doi.org/10.1023/A: 1024295710118
- 524 77. Vocale C, Bartoletti M, Rossini G, Macini P, Pascucci MG, Mori F, et al. Toscana Virus Infections
- 525 in Northern Italy: Laboratory and Clinical Evaluation. Vector-Borne Zoonotic Dis .
- 526 2012;12(6):526–9. DOI: https://doi.org/10.1089/vbz.2011.0781